Development of a novel, pan-variant aerosol intervention for COVID-19
R. H. Shoemaker, R. A. Panettieri, S. K. Libutti, H. S. Hochster, N. R. Watts, P. T. Wingfield, P. M. Starkl, L. Pimenov, R. Gawish, A. Hladik, S. Knapp, D. Boring, J. M. White, Q. Lawrence, J. Boone, , G. Wirnsberger
This paper reports preclinical development and evaluation of aerosolized soluble recombinant human ACE2 (APN01) as a COVID-19 intervention.
bioRxiv · Sep 14, 2021 · PreprintPharmacology & Toxicology